ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr.

Premenstrual symptoms are distressing for up to 20% of reproductive-aged women and are associated with impairment in interpersonal or workplace functioning for at least 3-8%. Typical symptoms of ...

Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(2):157-170. Symptoms emerge in second half of menstrual cycle and subside within 4 days after onset of menstruation Alternatively, symptoms must ...

The state of Iowa will receive nearly $38 million after signing on to a settlement with Purdue Pharma and its owners, Iowa Attorney General Brenna Bird said.

Iowa to receive $37.8 million in opioid settlement funds from Purdue Pharma Up to half of that money will go directly to Iowa's Opioid Settlement Fund, while the other half will be divided among local ...

Attorney General Brenna Bird announced on Wednesday that Iowa has agreed to sign on to a $7.4 billion settlement with Purdue Pharma and its owners, the Sackler family.

Iowa will receive $37.8 million from a settlement with Purdue Pharma, the maker of OxyContin. The settlement resolves claims related to Purdue's role in the opioid crisis.

MONTPELIER -– Attorney General Charity Clark announced all 55 attorneys general, representing all eligible states and U.S. territories, have agreed to sign on to a $7.4 billion settlement with Purdue ...

Kentucky is set to receive $73.1 million from a new settlement with Purdue Pharma the company's owners, the Sackler family, Attorney General Russell Coleman announced Monday.

FRANKFORT, Ky. (KT) – Attorney General Russell Coleman has announced a further $73.1 million settlement with Purdue Pharma and the Sackler family for their role in Kentucky’s opioid crisis, bringing ...

The settlement also permanently ends the Sackler family’s control of Purdue Pharma, according to the Attorney General's office, and prohibits them from participating in the U.S. opioid industry.